To evaluate bone turnover markers in patients with AVP deficiency (AVP-D) compared to individuals with primary polydipsia (PP) and healthy controls (HC).
Key Findings:
25OH-vitamin D levels were lower in AVP-D compared to HC (P = .031).
Median CTX levels were lower in AVP-D (0.373 ng/mL) than in HC (0.592 ng/mL, P = .021).
Bone formation index (P1NP/CTX ratio) was higher in AVP-D than in HC (P = .036).
No significant differences in bone metabolism markers were observed between PP and the other groups.
Interpretation:
Patients with AVP-D showed reduced CTX levels and an increased P1NP/CTX ratio compared to HC, suggesting no major detrimental effects on bone metabolism.
Limitations:
Small sample size may limit generalizability.
Exclusion of patients on certain medications may affect results.
Conclusion:
The findings do not support significant bone metabolic alterations in AVP-D, indicating that AVP deficiency may not have major detrimental effects on bone health.
Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.
